New antibody drug may boost transplant success in tough lymphoma
NCT ID NCT07387848
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests glofitamab, an antibody that helps immune cells attack lymphoma, in 40 adults with relapsed or refractory diffuse large B-cell lymphoma who are eligible for a stem cell transplant. Glofitamab is given before transplant as a 'bridge' to shrink the cancer, and again after transplant to prevent relapse. The study aims to see if this approach improves how long patients stay cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- glofitamab
- What this could lead to
- If successful, glofitamab could improve the chance of keeping lymphoma in remission after a stem cell transplant, offering a new option for patients who cannot access CAR-T therapy.
- What could go wrong
- This is a small, early-phase study with only 40 people, so results may not apply to everyone. Glofitamab can cause immune-related side effects, and it is not yet proven to be better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a drug duo outsmart returning lymphoma?